1.83
0.00%
+0.00
After Hours:
1.83
Trinity Biotech Plc ADR stock is currently priced at $1.83, with a 24-hour trading volume of 4,235.
It has seen a +0.00% increased in the last 24 hours and a -9.41% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $1.87 pivot point. If it approaches the $1.79 support level, significant changes may occur.
Previous Close:
$1.83
Open:
$1.83
24h Volume:
4,235
Market Cap:
$13.98M
Revenue:
$71.39M
Net Income/Loss:
$-28.60M
P/E Ratio:
-2.2649
EPS:
-0.808
Net Cash Flow:
$-12.92M
1W Performance:
+1.36%
1M Performance:
-9.41%
6M Performance:
+307.57%
1Y Performance:
+77.67%
Trinity Biotech Plc ADR Stock (TRIB) Company Profile
Name
Trinity Biotech Plc ADR
Sector
Industry
Phone
353 1 276 9800
Address
IDA Business Park, Bray
Trinity Biotech Plc ADR Stock (TRIB) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-23-15 | Downgrade | Craig Hallum | Buy → Hold |
Sep-03-15 | Initiated | Raymond James | Outperform |
Jul-29-15 | Reiterated | ROTH Capital | Buy |
Jul-22-08 | Reiterated | Roth Capital | Buy |
Mar-17-08 | Reiterated | Roth Capital | Buy |
Dec-10-07 | Reiterated | Roth Capital | Buy |
Oct-26-07 | Reiterated | Roth Capital | Buy |
View All
Trinity Biotech Plc ADR Stock (TRIB) Latest News
Trinity Biotech Announces Fourth Quarter and Fiscal Year 2023 Financial Results & Business Updates
GlobeNewswire Inc.
Trinity Biotech plc to Announce Q4 and Fiscal Year 2023 Financial Results
GlobeNewswire Inc.
Trinity Biotech Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
GlobeNewswire Inc.
Trinity Biotech Plc Finalizes Effective Date of ADS Ratio Change
GlobeNewswire Inc.
Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change
GlobeNewswire Inc.
Trinity Biotech to Present at Emerging Growth Conference
GlobeNewswire Inc.
Trinity Biotech Plc ADR Stock (TRIB) Financials Data
Trinity Biotech Plc ADR (TRIB) Revenue 2024
TRIB reported a revenue (TTM) of $71.39 million for the quarter ending September 30, 2023, a +7.64% rise year-over-year.
Trinity Biotech Plc ADR (TRIB) Net Income 2024
TRIB net income (TTM) was -$28.60 million for the quarter ending September 30, 2023, a +11.18% increase year-over-year.
Trinity Biotech Plc ADR (TRIB) Cash Flow 2024
TRIB recorded a free cash flow (TTM) of -$12.92 million for the quarter ending September 30, 2023, a -125.17% decrease year-over-year.
Trinity Biotech Plc ADR (TRIB) Earnings per Share 2024
TRIB earnings per share (TTM) was -$3.74 for the quarter ending September 30, 2023, a +30.68% growth year-over-year.
About Trinity Biotech Plc ADR
Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.
Cap:
|
Volume (24h):